Suresh S. Ramalingam, MD, professor of hematology and medical oncology at the Emory University School of Medicine, discusses the challenge of brain metastases in <em>EGFR</em>-mutated lung cancer and the data surrounding osimertinib (Tagrisso) in this patient population.
Suresh S. Ramalingam, MD, professor of hematology and medical oncology at the Emory University School of Medicine, discusses the challenge of treating brain metastases inEGFR-mutated lung cancer and the data surrounding osimertinib (Tagrisso) in this patient population.
In the FLAURA trial, presented at the 2019 European Lung Cancer Congress, osimertinib showed intracranial responses.
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More